腹膜透析患者腹膜白细胞介素-6对生存的预测作用
结果显示透析液IL-6随时间升高并伴随腹膜溶质转运率增加,血浆IL-6亦随时间升高且与透析液IL-6升高及残余肾功能下降相关;但仅血浆IL-6与死亡风险相关,透析液IL-6对死亡的预测能力弱且不改善血浆IL-6的预测。
要点
- 透析液IL-6随时间升高并伴随腹膜溶质转运率增加。
- 血浆IL-6而非透析液IL-6承载死亡风险。
- 改善生存的抗炎干预应靶向全身而非腹膜炎症。
核心结论
- 透析液IL-6升高可能独立于肾功能下降促进腹膜溶质转运率增加和全身炎症,但死亡风险由血浆IL-6承载。
- 未来改善患者生存的抗炎干预应靶向全身而非腹膜炎症。
研究设计与样本
- 透析液和血浆IL-6采用电化学发光法(Meso-Scale Discovery)检测,使用线性混合模型及单变量或双变量联合纵向生存模型分析。
主要发现
- 透析液IL-6水平随时间升高(每年1.14 pg/ml,95%CI:1.10-1.19),并伴随腹膜溶质转运率增加(P=0.001)。
- 血浆IL-6水平随时间升高(每年1.07 pg/ml,95%CI:1.04-1.10),与透析液IL-6升高(P<0.001)及残余肾功能下降(P=0.01)相关。
- 任意时间点估计的透析液IL-6对死亡的预测能力弱(AUC:0.57),且未改善血浆IL-6对死亡的预测(联合AUC:0.79,仅血浆IL-6 AUC:0.81)。
临床怎么用
- 临床监测腹膜透析患者全身炎症(血浆IL-6)比监测腹膜局部炎症(透析液IL-6)对死亡风险分层更有价值。
- 未来抗炎治疗试验应优先靶向全身炎症以改善腹膜透析患者生存。
局限性
- 研究纳入起始腹膜透析90天内且有至少3对纵向样本的患者,可能存在选择偏倚。
- 透析液IL-6对死亡的预测AUC仅0.57,预测能力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Systemic inflammation predicts cardiovascular events and mortality in patients on peritoneal dialysis (PD). Peritoneal inflammation potentially causes adverse outcomes by increasing peritoneal solute transfer rates (PSTRs); however, the extent to which it contributes to systemic inflammation is uncertain. We sought to quantify the longitudinal interrelationship between peritoneal and systemic inflammation, to understand whether peritoneal or systemic inflammation should be targeted to reduce mortality. METHODS: We used patients recruited to the GLOBAL Fluid Study (GFS) within 90 days of starting PD, with ≥ 3 longitudinal paired dialysate and plasma samples. These were assayed for dialysate and plasma interleukin (IL)-6 levels by electrochemiluminescence (Meso-Scale Discovery, Gaithersburg, MD). Linear mixed models and univariate or bivariate joint longitudinal survival modelling were used. RESULTS: Two hundred seventeen patients with 1273 measurements were included. Dialysate IL-6 levels increased with time (1.14 pg/ml/yr on PD, 95% confidence interval [CI]: 1.10-1.19), with an associated increase in PSTR (P = 0.001). Plasma IL-6 levels increased over time (1.07 pg/ml/yr on PD, 95% CI: 1.04-1.10), with an associated increase in dialysate IL-6 (P < 0.001) and reduction in residual kidney function (P = 0.01). Dialysate IL-6 levels estimated at any given time point weakly predicted mortality area under the curve (AUC: 0.57) and did not improve the prediction of mortality by plasma IL-6 (combined dialysate/plasma IL-6 AUC: 0.79, plasma IL-6 only AUC 0.81). CONCLUSION: Although rising dialysate IL-6 levels may contribute to rising PSTR and increasing systemic inflammation independently of declining kidney function over time, it is plasma IL-6 that confers mortality risk. This suggests future antiinflammatory interventions to improve patient survival should target systemic rather than peritoneal inflammation.
引用
- Elphick EH, Zavvos V, Belcher J, et al. The Role of Peritoneal Interleukin-6 in Predicting Patient Survival on Peritoneal Dialysis. Kidney Int Rep. 2025. PMID: 40980662. doi:10.1016/j.ekir.2025.06.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。